Stateside researchers working in the fightback against cancer have said that vaccines which shrink tumours and prevent them from returning may be available in as little as five years time. Following on from decades of trialling and testing to no avail, scientists say that their research has reached a turning point.
And while the shots are being called vaccines, they don't work in the same vein as traditional boosters which prevent diseases. Instead, they shrink tumours and stop them from returning to the affected site.
Breast and lung cancer are types of the disease which are being targeted by the experimental treatment - with gains also reported in 2023 for melanoma and pancreatic cancers. Volunteer patients have said that they are participating in the trials not only with hopes of shrinking their own tumours, but to also help those in future who suffer the devastating disease.
Read more: Flash mob takes place at Angel of the North for cervical cancer awareness
The Mirror reports that Dr James Gully, who helps lead a centre at the National Cancer Institute, said: "We're getting something to work. Now we need to get it to work better."
Following years of research, scientists now have a better understanding of how cancer hides from the body's immune system - citing how vaccines, like other immunotherapies, boost the immune system so it can find and kill cancerous cells. Some of the newer ones use mRNA, which was initially developed in the fight against cancer but was introduced into the first Covid vaccines.
In order for a vaccine to work, it has to be able to reach T cells to recognise them as dangerous - Dr Nora Disis of UW Medicine's Cancer Vaccine Institute in Seattle explained. Once T cells are trained, they can travel anywhere in one's body to sniff out danger.
She said: "If you saw an activated T cell, it almost has feet. You can see it crawling through the blood vessel to get out into the tissues."
Patient volunteers, like 50year-old Kathleen Jade, are vital to the research. She was diagnosed with breast cancer in February, just weeks before she was due to leave Seattle with her husband for a world-wide adventure. Instead, she was confined to a hospital waiting for her third dose of an experimental vaccine.
She's been receiving the therapy ahead of her surgery, in hopes that it will shrink her tumours. She said: "Even if that chance is a little bit, I felt like it's worth it."
Progress has been challenging since research started, with the first vaccine in Provenge approved across the US in 2010 to treat spreading prostate cancer. It requires a patient's own immune cells in a lab, before these are reembodied intravenously.
There are also stateside vaccines for early bladder cancer and advanced melanoma. Furthermore, future cancer preventing vaccines may appear too, with decade-old Hepatitis B vaccines preventing liver cancer, and HPV vaccines - presented in 2006 - preventing cervical cancer in their own right.
Early cancer vaccine research faltered as cancer outwitted and outlasted patients' weakened immune systems, said vaccine researcher Olja Finn, based at the University of Pittsburgh School of Medicine. Ms Finn, added: "All of these trials that failed allowed us to learn so much.
As a result, she now focusing on patients with earlier disease since the experimental vaccines did not help with more advanced patients. Her group is planning a vaccine study in women with a low-risk, non-invasive breast cancer called ductal carcinoma in situ. In Philadelphia, Dr Susan Domchek, director of the Basser Center at Penn Medicine, is recruiting 28 healthy people with the BRCA mutation for a vaccine test.
The mutation is known to increase the risk of breast and ovarian cancer. The idea is to kill very early abnormal cells before they cause problems. She likens it to periodically weeding a garden or erasing a whiteboard.
Others are developing vaccines to prevent cancer in people with precancerous lung nodules and other inherited conditions that increase cancer risk.
"Vaccines are probably the next big thing" in the fight to reduce cancer deaths, said Dr Steve Lipkin, a medical geneticist at New York's Weill Cornell Medicine. He is leading one effort funded by the National Cancer Institute. "We're dedicating our lives to that", he added.
People with the inherited condition Lynch syndrome have a 60 to 80 per cent lifetime risk of developing cancer. Recruiting them for cancer vaccine trials has been remarkable easy, according to Dr Eduardo Vilar-Sanchez of MD Anderson Cancer Centre in Houston, who is leading two government-funded studies on vaccines for Lynch-related cancers.
"Patients are jumping on this in a surprising and positive way," he said.
Moderna and Merck are jointly developing a personalised mRNA vaccine for patients with melanoma, with a large study to begin this year. The vaccines are customised to each patient, based on the numerous mutations in their cancer tissue. A vaccine personalised in this way can train the immune system to hunt for the cancer's mutation fingerprint and kill those cells.
However, these vaccines will be expensive.
"You basically have to make every vaccine from scratch," said Dr Patrick Ott of Dana-Farber Cancer Institute in Boston. "If this was not personalised, the vaccine could probably be made for pennies, just like the Covid vaccine."
The vaccines under development at UW Medicine are designed to work for many patients, not just a single patient. Tests are under way in early and advanced breast cancer, lung cancer and ovarian cancer. Some results could be seen as soon as next year.
